Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,144 public trials 2,036 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, not recruiting

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT01886872

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 937 locations
View Trial Details
Active, not recruiting

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02048813

Conditions
Anemia, Chronic Disease, Chronic Lymphocytic Leukemia, +16 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 781 locations
View Trial Details
Active, not recruiting

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

NCT06934044

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Sun yat-sen University Cancer Center Guangzhou, Guangdong, China
  • Tianjin Institute of Hematology & Blood Diseases Hospital Tianjin, Tianjin Municipality, China
  • The First Affiliated Hospital of Nanchang University Nanchang, China
  • The First Affiliated Hospital of Wenzhou Medical University Wenzhou, China
View Trial Details
Active, not recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCSF Fresno Clovis, California, United States
  • UCLA Santa Monica, California, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Medical Oncology Hematology Consultants, PA Newark, Delaware, United States
View all 242 locations
View Trial Details
Active, not recruiting

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT05424822

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • City of Hope Duarte, California, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
View all 29 locations
View Trial Details
Active, not recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • City of Hope Duarte, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • Yale University New Haven, Connecticut, United States
View all 176 locations
View Trial Details
Active, not recruiting

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham - Main /ID# 261434 Birmingham, Alabama, United States
  • Mayo Clinic Hospital - Phoenix /ID# 263326 Phoenix, Arizona, United States
  • Alta Bates Summit Medical Center for Research /ID# 261438 Berkeley, California, United States
  • Providence - St. Jude Medical Center /ID# 262031 Fullerton, California, United States
View all 166 locations
View Trial Details
Active, not recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

NCT04464200

Conditions
Blood Protein Disorders, Burkitt Lymphoma, Burkitt's Lymphoma, +41 more
Locations
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities) Commack, New York, United States
View Trial Details
Active, not recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT04077723

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • City of Hope Medical Center Pasadena, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 35 locations
View Trial Details

Related conditions